Contraindications for the use of pomalidomide

Pomalidomide (Pomalidomide) is an immunomodulatory drug commonly used to treat multiple myeloma (MM), especially in patients who have relapsed and refractory after failure of other treatments. However, due to its powerful pharmacological effects, the use of pomalidomide is accompanied by some contraindications, especially for pregnant women and patients with certain allergies.

Pomalidomide is contraindicated in pregnant women: Pomalidomide is a thalidomide analogue that can cause serious harm to the fetus by acting on the reproductive system of pregnant women. Clinical studies have shown that pomalidomide use during pregnancy may cause fetal developmental abnormalities, including structural malformations and organ hypoplasia. Teratogenic effects have been shown in animal experiments (including rats and rabbits) when administered during organogenesis. Therefore, pomalidomide should be strictly avoided in pregnant women. If a woman becomes pregnant during treatment, the drug should be discontinued immediately and an appropriate evaluation of the potential risk to the fetus should be considered.

In practical applications, in order to prevent pregnant women from becoming pregnant during use, patients usually need to take a pregnancy test before receiving treatment and use effective contraceptive measures. During treatment, female patients and male patients (especially those who may affect pregnancy) should also continue to use contraceptive measures until at least one month after the end of treatment. If a patient becomes pregnant during treatment, they must communicate with their doctor promptly to evaluate the risks posed by the drug and consider other treatment options.

Hypersensitivity Contraindications: This drug should also not be used in people who have exhibited a severe allergic reaction (such as angioedema or anaphylactic shock) to pomalidomide or any of its excipients (such as certain ingredients in the drug). Severe allergic reactions may be life-threatening and require immediate discontinuation of the drug and appropriate first aid treatment. Therefore, before starting treatment, the patient's allergy history should be carefully inquired to ensure that the patient is not allergic to the drug ingredients.

Reference materials:https://www.medicines.org.uk/emc/product/1262/smpc